ArticleJournal of medical ultrasonics (2001)2019
Clinical application of ultrasound-guided percutaneous microwave ablation in the treatment of T1aN0M0 stage renal carcinoma.
Article in Journal of medical ultrasonics (2001), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Computed Tomography-Guided Percutaneous Microwave Ablation for Renal Cell Carcinoma: Impact of Tumor Size on the Progression Survival Rates.Diagnostics (Basel, Switzerland) · 2021Article
- Application value of dual-energy computed tomography spectrum curve combined with clinical risk factors in predicting adherent perinephric fat.Quantitative imaging in medicine and surgery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvaluation of clinical application of ultrasound-guided percutaneous microwave ablation treatment for T1a renal carcinoma.
methodsAnalysis of the clinical data from 31 patients with T1aN0M0 stage renal carcinoma who underwent ultrasound-guided percutaneous microwave ablation in the Department of Ultrasound of China-Japan Union Hospital of Jilin University between March 2010 and June 2014.
resultsAll of the 31 patients were treated with ablation only once: 96.8% (30/31) of patients had no local recurrence or distant metastasis after ablation. One (3.2%) patient had local tumor recurrence 6 months after surgery and underwent a second microwave ablation. According to the results of 2 years of follow-up re-examinations, no further recurrence or distant metastasis was found. Moreover, 90.3% (28/31) of the patients had no complications with normal ranges of preoperative and postoperative serum creatinine and urea nitrogen levels. Complications were found in 9.7% (3/31) of the patients: one case of transient hematuria, one case of perirenal hematoma, and one case of cholecystitis; the symptoms were resolved with symptomatic treatment.
conclusionUltrasound-guided percutaneous microwave ablation is a safe and effective micro-invasive therapy for T1a renal cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.